New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
13:25 EDTJNJEarnings Preview: J&J looking for another strong performance in pharmaceuticals
Johnson & Johnson (JNJ) is scheduled to report first quarter earnings before the market open on Tuesday, April 15, with a conference call scheduled for 8:30 am ET. Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. EXPECTATIONS: Analysts are looking for earnings per share of $1.48 on revenue of $18.0B, according to First Call. The consensus range for EPS is $1.41-$1.55 on revenue of $17.83B-$18.32B. LAST QUARTER: Johnson & Johnson reported fourth quarter EPS of $1.24 against estimates of $1.20 on revenue of $18.4B against estimates of $17.95B. The company gave a fiscal year EPS view of $5.75-$5.85 against a consensus estimate of $5.85. The company noted that the primary contributors to operational sales growth in 2013 include Remicade, Simponi, Stelera, Zytiga, and Prezista. Sales results for the year were negatively impacted by loss of exclusivity for AcipHex/Pariet, a proton pump inhibitor for gastrointestinal disorders and Concerta for the treatment of attention deficit hyperactivity disorder. STREET RESEARCH: On April 14, Jefferies downgraded its rating on Johnson & Johnson to Hold from Buy citing the recent outperformance of shares. The firm kept a $105 price target for the stock. PRICE ACTION: Shares of Johnson & Johnson are up approximately 2% since its last earnings report, and are trading hear flat in afternoon trading.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 29, 2015
14:06 EDTJNJJ&J announces study findings of paliperidone palmitate published in JAMA
Subscribe for More Information
March 27, 2015
15:14 EDTJNJJohnson & Johnson not likely to buy Intuitive Surgical, says BofA/Merrill
Subscribe for More Information
09:59 EDTJNJJohnson & Johnson to collaborate with Google to advance surgical robots
Subscribe for More Information
06:46 EDTJNJContact lens makers, discounters battling over price setting, NY Times says
Subscribe for More Information
March 25, 2015
07:29 EDTJNJLeerink to hold booth tours
Leerink Booth Tours at AAOS 2015 will be held in Las Vegas on March 25-26.
March 24, 2015
13:24 EDTJNJContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
07:45 EDTJNJFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
March 23, 2015
09:03 EDTJNJLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 17, 2015
05:35 EDTJNJJohnson & Johnson to invest $10M in UK government fund to fight dementia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use